Tibsovo

Active Ingredient(s): Ivosidenib
FDA Approved: * July 20, 2018
Pharm Company: * AGIOS PHARMACEUTICALS INC
Category: Cancer

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.[1] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and for cholangiocarcinoma.[2][3][4][5] Ivosi... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tibsovo 250 mg Oral Tablet, Film Coated
NDC: 71334-100
Labeler:
Agios Pharmaceuticals, Inc.